Inventor
KYRATSOUS CHRISTOS
US38 patents
⚠️ This page may combine multiple inventors who share the name “KYRATSOUS CHRISTOS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
34 patentsUS10787501B1Sep 29, 2020
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA224 citations98
US10975139B1Apr 13, 2021
Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA15 citations93
US10954289B1Mar 23, 2021
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA28 citations93
US10501526B2Dec 10, 2019
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA11 citations92
US10081670B2Sep 25, 2018
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA10 citations92
US9771414B2Sep 26, 2017
Human antibodies to ebola virus glycoprotein
REGENERON PHARMA18 citations92
US11208458B2Dec 28, 2021
Compositions and methods for internalizing enzymes
REGENERON PHARMA28 citations91
US9718872B2Aug 1, 2017
Human antibodies to middle east respiratory syndrome—coronavirus spike protein
REGENERON PHARMA18 citations91
US11259510B2Mar 1, 2022
Humanized T cell mediated immune responses in non-human animals
REGENERON PHARMA8 citations86
US10421804B2Sep 24, 2019
Anti-Zika virus antibodies and methods of use
REGENERON PHARMA11 citations84
US9532555B2Jan 3, 2017
Humanized dipeptidyl peptidase IV (DPP4) animals
REGENERON PHARMA4 citations83
US9497945B2Nov 22, 2016
Humanized dipeptidyl peptidase IV (DPP4) animals
REGENERON PHARMA5 citations83
US11530255B2Dec 20, 2022
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA3 citations73
US11117955B2Sep 14, 2021
Anti-Zika virus antibodies and methods of use
REGENERON PHARMA4 citations73
US10829544B2Nov 10, 2020
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA2 citations73
US11732030B2Aug 22, 2023
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA2 citations72
US10406222B2Sep 10, 2019
Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein
REGENERON PHARMA4 citations72
US10212923B2Feb 26, 2019
Humanized dipeptidyl-peptidase IV (DPP4) animals
REGENERON PHARMA1 citations72
US12404505B2Sep 2, 2025
Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
REGENERON PHARMA0 citations62
US12256720B2Mar 25, 2025
Humanized dipeptidyl-peptidase IV (DPP4) animals
REGENERON PHARMA0 citations62
US12251440B2Mar 18, 2025
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA0 citations62
US12152067B2Nov 26, 2024
Human antibodies to ebola virus glycoprotein
REGENERON PHARMA0 citations62
US11013220B2May 25, 2021
Humanized dipeptidyl-peptidase IV (DPP4) animals
REGENERON PHARMA0 citations62
US12497460B2Dec 16, 2025
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA0 citations61
US12459991B2Nov 4, 2025
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
REGENERON PHARMA0 citations61
US11999799B2Jun 4, 2024
Anti-TMPRSS2 antibodies and antigen-binding fragments
REGENERON PHARMA0 citations61
US11773156B2Oct 3, 2023
Anti-hemagglutinin antibodies and methods of use thereof
REGENERON PHARMA0 citations61
US11377502B2Jul 5, 2022
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA1 citations61
US12552856B2Feb 17, 2026
Anti-PCRV antibodies that bind PCRV, compositions comprising anti-PCRV antibodies, and methods of use thereof
REGENERON PHARMA0 citations59
US12215138B2Feb 4, 2025
Compositions and methods for internalizing enzymes
REGENERON PHARMA0 citations59
US11655286B2May 23, 2023
Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
REGENERON PHARMA0 citations59
US12024556B2Jul 2, 2024
Anti-Staphylococcus antibodies and uses thereof
REGENERON PHARMA0 citations56
US12496470B2Dec 16, 2025
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA0 citations51
US11696572B2Jul 11, 2023
Non-human animals comprising a humanized ASGR1 locus
REGENERON PHARMA0 citations50
DECIBEL THERAPEUTICS INC
3 patentsUS12252520B2Mar 18, 2025
Myosin 15 promoters and uses thereof
DECIBEL THERAPEUTICS INC2 citations70
US12410442B2Sep 9, 2025
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
DECIBEL THERAPEUTICS INC0 citations58
US12589168B2Mar 31, 2026
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
DECIBEL THERAPEUTICS INC0 citations47